

ARD

Annals of the Rheumatic Diseases
The EULAR Journal

Editor

Leo van de Putte (The Netherlands)

Associate editors

Thomas Bardin (France)
Johannes Bijlsma (The Netherlands)
Gerd Burmester (Germany)

Methodological adviser

Jaap Fransen (The Netherlands)

Editorial board

M Aringer (Austria)
P Bacon (UK)
F Berenbaum (France)
M Boers (The Netherlands)
D Boumpas (Greece)
B Bresnihan (Ireland)
H Capell (UK)
M Cutolo (Italy)
G Firestein (USA)
P Goupille (France)
E Gravalles (USA)
W Gross (Germany)
F Guillemin (France)
G Herrero-Beaumont (Spain)
F Houssiau (Belgium)
T Huizinga (The Netherlands)
C Jorgensen (France)
G Kollias (Greece)
T Kvien (Norway)
M Leirisalo-Repo (Finland)
F Luijten (Belgium)
H-M Lorenz (Germany)
W Maslinski (Poland)
M Matucci Cerinic (Italy)

Advisory committee

W vd Berg (The Netherlands)
S Bombardieri (Italy)
F Breedveld (The Netherlands)
L Crofford (USA)
J-M Dayer (Switzerland)
M Doherty (UK)
M Dougados (France)
J Edmonds (Australia)
P Emery (UK)
D Furst (USA)
S Gay (Switzerland)
J Kalden (Germany)
E Keystone (Canada)
L Klareskog (Sweden)

Bevrah Hahn (USA)
Frank Wollheim (Sweden)
Anthony Woolf (UK)

K Nishioka (Japan)
M Nurmohamed
(The Netherlands)
S Özen (Turkey)
T Pap (Germany)
E Pascual Gómez (Spain)
L Punzi (Italy)
L Rönnblom (Sweden)
B Rozman (Slovenia)
G Schett (Austria)
J Da Silva (Portugal)
H Schulze-Koops (Germany)
A So (Switzerland)
T Sokka (USA)
D Symmons (UK)
P-P Tak (The Netherlands)
A Tyndall (Switzerland)
A Tzioufas (Greece)
J Vencovsky (Czech Republic)
M Ward (USA)
M Weisman (USA)
H Yazici (Turkey)
Editor, *BMJ*

P Lipsky (USA)
S Lohmander (Finland)
R Maini (UK)
E M Mola (Spain)
H Moutsopoulos (Greece)
J O'Dell (USA)
K Pavelka (Czech Republic)
J Rovinsky (Slovakia)
Y Shoenfeld (Israel)
J Smolen (Austria)
W van Venrooy
(The Netherlands)
E Veys (Belgium)
A Wiik (Denmark)

Guidelines for authors and reviewers

Guidance for authors and reviewers can be found at <http://ard.bmj.com/fora>
All papers must be submitted via Bench>Press at www.submit-ard.bmj.com

Disclaimer

Annals of the Rheumatic Diseases is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association, and the European League Against Rheumatism.

The BMA grants editorial freedom to the Editor of the *Annals of the Rheumatic Diseases*. The *Annals of the Rheumatic Diseases* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

The *Annals of the Rheumatic Diseases* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, The European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement. To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of the *Annals of the Rheumatic Diseases* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Subscription information

See p iv
ISSN 0003-4967 (print); 1468-2060 (online)


Copyright

© 2007 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*

Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at <http://annrheumdis.com/fora/licence.dtl>

• *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, copyedited by Macmillan India Ltd, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Cambrian Printers Limited, Aberystwyth

• Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



Microscopic manifestations of synovitis (A) and enthesitis (B) in aged MCF2 mice. See p 242

contents ARD

Volume 66 Number 2 February 2007

Editorial

- 141 Overweight: advancing our understanding of its impact on the knee and the hip *L Sharma, A Chang*

Review

- 143 Consensus statement on the use of rituximab in patients with rheumatoid arthritis *J S Smolen, E C Keystone, P Emery, F C Breedveld, N Betteridge, G R Burmester, M Dougados, G Ferraccioli, U Jaeger, L Klareskog, T K Kvien, E Martin-Mola, K Pavelka, The Working Group on the Rituximab Consensus Statement*

Extended reports

- 151 Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with down regulation only on monocytes in responders *T Ellingsen, N Hornung, B K Møller, J H Poulsen, K Stengaard-Pedersen*
- 158 Body mass index associated with onset and progression of osteoarthritis of the knee but not of the hip: The Rotterdam Study *M Reijman, H A P Pols, A P Bergink, J M W Hazes, J N Belo, A M Lievense, S M A Bierma-Zeinstra*
- 163 Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial *D D Gladman, P J Mease, M A Cifaldi, R J Perdok, E Sasso, J Medich*
- 169 Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test *M H Buch, C P Denton, D E Furst, L Guillevin, L J Rubin, A U Wells, M Matucci-Cerinic, G Riemekasten, P Emery, H Chadha-Boreham, P Charef, S Roux, C M Black, J R Seibold*
- 174 Abdominal manifestations in childhood-onset systemic lupus erythematosus *O Richer, T Ulinski, I Lemelle, B Ranchin, C Loirat, J C Piette, P Pillet, P Quartier, R Salomon, B Bader-Meunier, for the French Pediatric-Onset SLE Study Group*
- 179 Perinatal and early childhood risk factors associated with rheumatoid factor positivity in a healthy paediatric population *K A Young, L A Parrish, G O Zerbe, M Rewers, K D Deane, V M Holers, J M Norris*
- 184 Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis *V P van Halm, M M J Nielsen, M T Nurmohamed, D van Schaardenburg, H W Reesink, A E Voskuyl, J W R Twisk, R J van de Stadt, M H M T de Koning, M R Habibuw, I E van der Horst-Bruinsma, B A C Dijkmans*
- 189 Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment *A S Russell, G V Wallenstein, T Li, M C Martin, R Maclean, B Blaisdell, K Gajria, J C Cole, J-C Becker, P Emery*
- 195 Rheumatoid arthritis and genetic markers in Syrian and French populations: different effect of the shared epitope *L Kazkaz, H Marotte, M Hamwi, M A Cazalis, P Roy, B Mouglin, P Miossec*
- 202 Haematopoietic stem cell transplantation for vasculitis including Behçet's disease and polycondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature *T Daikeler, I Kötter, C Bocelli Tyndall, J Apperley, A Attarbaschi, P Guardiola, A Gratwohl,*



www.publicationethics.org.uk

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

- E Jantunen, A Marmont, F Porretto, M Musso, B Maurer, N Rinaldi, R Saccardi, A Tyndall, for the EBMT Autoimmune Diseases Working Party*
- 208 High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors *C P Chung, I Avalos, A Oeser, T Gebretsadik, A Shintani, P Raggi, C M Stein*
- 215 The cost effectiveness of behavioural graded activity in patients with osteoarthritis of hip and/or knee *V M H Coupé, C Veenhof, M W van Tulder, J Dekker, J W J Bijlsma, C H M Van den Ende*
- 222 Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies *R Watts, S Lane, T Hanslik, T Hauser, B Hellmich, W Koldingsnes, A Mahr, M Segelmark, J W Cohen-Tervaert, D Scott*
- 228 Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial *M Weinblatt, M Schiff, A Goldman, J Kremer, M Luggen, T Li, D Chen, J-C Becker*
- 235 Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study *H A Capell, R Madhok, D R Porter, R A L Munro, I B McInnes, J A Hunter, M Steven, A Zoma, E Morrison, M Sambrook, F W Poon, R Hampson, F McDonald, A Tierney, N Henderson, I Ford*
-
- Concise reports**
- 242 A non-major histocompatibility locus determines tissue specificity in the pathogenic process underlying synovial proliferation in a mouse arthropathy model *M-C Zhang, S Mori, F Date, H Furukawa, M Ono*
- 246 Influence of human leucocyte antigen-DRB1 on the production of anti-cyclic citrullinated peptide antibodies in a Portuguese population *D Ligeiro, J E Fonseca, O Abade, I Abreu, M Cruz, P Nero, J Cavaleiro, J Teles, H Trindade, J M Caetano, J Branco*
- 249 Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects *F Iannone, F Trotta, C Montecucco, R Giacomelli, M Galeazzi, M Matucci-Cerinic, C Ferri, M Cutolo, L M Bambara, G Triolo, G Ferraccioli, G Valentini, G Lapadula, on behalf of GISEA (Gruppo Italiano per lo Studio delle Early Arthritis)*
- 253 Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis *C J van der Laken, A E Voskuyl, J C Roos, M Stigter van Walsum, E R de Groot, G Wolbink, B A C Dijkmans, L A Aarden*
- 257 Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients *Y Allanore, D Borderie, P Airo, S Guiducci, L Czirák, E L Nasonov, G Riemekasten, P Caramaschi, M Majdan, D Krasowska, E Friedl, H Lemarchal, L P Ananieva, T Nievskaya, O G Ekindjian, M Matucci-Cerinic, A Kahan*
- 260 Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis *B A Biggee, C M Blinn, M Nuite, J E Silbert, T E McAlindon*
- 263 Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis *A Södergren, B Stegmayr, V Lundberg, M-L Öhman, S Wållberg-Jonsson*
- 267 Rheumatoid factor seropositivity is inversely associated with oral contraceptive use in women without rheumatoid arthritis *S S Bhatia, D S Majka, J M Kittelson, L A Parrish, E D Ferucci, K D Deane, W P Arend, M Rewers, V M Holers, J M Norris*
-
- Letters**
- 270 Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience *P V Voulgari, A I Venetsanopoulou, E K Epagelis, Y Alamanos, I Takalou, A A Drosos*
- 271 Prevalence and risk factors of discordance in diagnosis of osteoporosis using spine and hip bone densitometry *A El Maghraoui, D A M Abay, I Ghozlani, A Mounach, A Nouijai, M Ghazi, L Achemlal, A Bezza*
- 273 Investigation of association of the *DLG5* gene with psoriatic arthritis *P Ho, J Worthington, I N Bruce, A Barton*
- 274 *MHC2TA* is associated with rheumatoid arthritis in Japanese patients *N Iikuni, K Ikari, S Momohara, T Tomatsu, M Hara, H Yamanaka, H Okamoto, N Kamatani*
- 276 QuantiFERON TB Gold Test: the new standard for screening of latent tuberculosis in patients with rheumatoid arthritis? *P Efthimiou, S Sood*
- 277 Dual mycobacterial infection in the setting of leflunomide treatment for rheumatoid arthritis *S Agrawal, A Sharma*
- 278 Demographics and environmental factors in a Wegener's granulomatosis cluster *J H M Lee, T Attygalle, K Gaffney, D G I Scott*
- 279 *MATN3* (matrilin-3) sequence variation (pT303M) is a risk factor for osteoarthritis of the CMC1 joint of the hand, but not for knee osteoarthritis *O Pullig, A Tagariello, A Schweizer, B Swoboda, P Schaller, A Winterpacht*
-
- 280 Forthcoming events